Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
Public ClinicalTrials.gov record NCT04863248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 trial evaluating the effect of trilaciclib on overall survival when administered prior to docetaxel in patients with metastatic NSCLC treated in the 2nd or 3rd line setting.
Study identification
- NCT ID
- NCT04863248
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 10 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2021 (Actual)
- Primary completion
- Feb 2, 2022 (Actual)
- Completion
- Feb 2, 2022 (Actual)
- Last update posted
- Apr 14, 2023
2021 – 2022
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer & Research Centers | Phoenix | Arizona | 85028 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| Desert Hematology Oncology Medical Group, Inc | Rancho Mirage | California | 92270 | — |
| Innovative Clinical Research Institute - Oncology | Whittier | California | 90602 | — |
| Mid-Florida Hematology Oncology | Orange City | Florida | 32763 | — |
| Indiana University Health Goshen Cancer Center | Goshen | Indiana | 46526 | — |
| St. Louis Cancer Care, LLP | Bridgeton | Missouri | 63044 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932 | — |
| Regional Cancer Car Associates, LLC | Little Silver | New Jersey | 07739 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Millennium Oncology | Houston | Texas | 77090 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04863248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 14, 2023 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04863248 live on ClinicalTrials.gov.